l-Asparaginase as the gold standard in the treatment of acute lymphoblastic leukemia: a comprehensive review

被引：0
作者：
María Tosta Pérez
Lisandra Herrera Belén
Pablo Letelier
Yolanda Calle
Adalberto Pessoa
Jorge G. Farías
机构：
[1] Universidad de La Frontera,Department of Chemical Engineering, Faculty of Engineering and Science
[2] Universidad Santo Tomas,Departamento de Ciencias Básicas, Facultad de Ciencias
[3] Universidad Católica de Temuco,Precision Health Research Laboratory, Departamento de Procesos Diagnósticos y Evaluación, Facultad de Ciencias de La Salud
[4] University of Roehampton,Department of Life Sciences, Whitelands College
[5] University of Sao Paulo,Department of Biochemical and Pharmaceutical Technology, School of Pharmaceutical Sciences
来源：
Medical Oncology | / 40卷
关键词：
Acute lymphoblastic leukemia; Asparaginase; Antineoplastic agent; Immunogenicity; Hypersensitivity;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
l-Asparaginase is an antileukemic drug long approved for clinical use to treat childhood acute lymphoblastic leukemia, the most common cancer in this population worldwide. However, the efficacy and its use as a drug have been subject to debate due to the variety of adverse effects that patients treated with it present, as well as the prompt elimination in plasma, the need for multiple administrations, and high rates of allergic reactions. For this reason, the search for new, less immunogenic variants has long been the subject of study. This review presents the main aspects of the l-asparaginase enzyme from a structural, pharmacological, and clinical point of view, from the perspective of its use in chemotherapy protocols in conjunction with other drugs in the different treatment phases.
引用
收藏
相关论文
共 334 条
[11]  
Onciu M(2017)Atomic resolution structure of Crit Rev Biotechnol 37 82-99
[12]  
Beckett A(2010)-asparaginase Curr Med Chem 17 2183-95
[13]  
Gervais D(2007)-Asparaginase as potent anti-leukemic agent and its significance of having reduced glutaminase side activity for better treatment of acute lymphoblastic leukaemia Crit Rev Oncol Hematol 61 208-221
[14]  
Müller HJ(2016)Crystal structure of Pediatr Blood Cancer 63 228-33
[15]  
Boos J(2017)-asparaginase, an enzyme used in cancer therapy Pediatr Blood Cancer 64 1-8
[16]  
Avramis VI(2014)Therapeutic l-asparaginase: upstream, downstream and beyond J Biocatal Biotransformation 2 1-9
[17]  
Tiwari PN(2001)Structure–function relationships asparaginases and clinical applications of l-asparaginases Br J Cancer 85 930-5
[18]  
Batool T(2016)Pharmacological and clinical evaluation of Crit Rev Oncol Hematol 100 1-10
[19]  
Makky EA(2017)-asparaginase in the treatment of leukemia Cancer Chemother Pharmacol 79 439-450
[20]  
Jalal M(2009)Activity and toxicity of intravenous Drug Eval 91 111-9
12345678910